Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

4.330 -0.170 (-3.78%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist

Price and Volume

Volume	220,605
Open	4.400
Bid (Size)	4.330 (100)
Ask (Size)	4.650 (4,600)
Prev. Close	4.500
Today's Range	4.310 - 4.527
52wk Range	0.7500 - 5.540
Shares Outstanding	54,808,715
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension ↗

May 12, 2026

Via Chartmill

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Performance

YTD	+58.6%	+58.6%
1 Month	-6.3%	-6.3%
3 Month	+90.7%	+90.7%
6 Month	+170.6%	+170.6%
1 Year	+373.7%	+373.7%

More News

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

April 20, 2026

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

April 20, 2026

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

April 15, 2026

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

March 17, 2026

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

March 10, 2026

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

February 05, 2026

From Equity Insider

Via GlobeNewswire

Why Did PRLD Stock Surge 13% Today? ↗

February 03, 2026

Via Stocktwits

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

February 03, 2026

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

December 06, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

December 16, 2025

From Equity Insider

Via GlobeNewswire

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

November 26, 2025

From Schall Law

Via GlobeNewswire

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

November 19, 2025

From Schall Law

Via GlobeNewswire

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

Via FinancialNewsMedia

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

From FN Media Group LLC

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗

November 12, 2025

Via Chartmill

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

November 11, 2025

From The Schall Law Firm

Via Business Wire

In today's session, these stocks are experiencing unusual volume. ↗

November 05, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Which stocks are experiencing notable movement on Tuesday? ↗

November 04, 2025

Via Chartmill

On Tuesday, there are stocks with unusual volume. Let's take a look. ↗

November 04, 2025

Via Chartmill

Tuesday's session: top gainers and losers ↗

November 04, 2025

Via Chartmill

Frequently Asked Questions

Is Prelude Therapeutics Incorporated - Common Stock publicly traded?

Yes, Prelude Therapeutics Incorporated - Common Stock is publicly traded.

What exchange does Prelude Therapeutics Incorporated - Common Stock trade on?

Prelude Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Prelude Therapeutics Incorporated - Common Stock?

The ticker symbol for Prelude Therapeutics Incorporated - Common Stock is PRLD on the Nasdaq Stock Market

What is the current price of Prelude Therapeutics Incorporated - Common Stock?

The current price of Prelude Therapeutics Incorporated - Common Stock is 4.330

When was Prelude Therapeutics Incorporated - Common Stock last traded?

The last trade of Prelude Therapeutics Incorporated - Common Stock was at 05/21/26 04:00 PM ET

What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?

The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 237.32M

How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?

Prelude Therapeutics Incorporated - Common Stock has 237M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.